Literature DB >> 2189869

Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment.

P Braun1, D Greenberg, H Dasberg, B Lerer.   

Abstract

The authors report a random-assignment, double-blind crossover trial comparing alprazolam and placebo in posttraumatic stress disorder (PTSD). Ten patients fulfilling DSM-III criteria for PTSD completed 5 weeks of treatment on each agent. Improvement in anxiety symptoms was significantly greater during alprazolam treatment but modest in extent. Symptoms specific to PTSD were not significantly altered. The impact of nonspecific symptomatic effects on the outcome of drug trials in PTSD is considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189869

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

1.  Pathophysiological mechanisms underlying increased anxiety after soman exposure: reduced GABAergic inhibition in the basolateral amygdala.

Authors:  Eric M Prager; Volodymyr I Pidoplichko; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Neurotoxicology       Date:  2014-08-20       Impact factor: 4.294

Review 2.  Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Authors:  William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

3.  Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.

Authors:  Kathryn M Connor; Jonathan R T Davidson; Richard H Weisler; Wei Zhang; Kurian Abraham
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

4.  A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder.

Authors:  D G Baker; B I Diamond; G Gillette; M Hamner; D Katzelnick; T Keller; T A Mellman; E Pontius; M Rosenthal; P Tucker
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 5.  New directions in the pharmacotherapy of posttraumatic stress disorder.

Authors:  Charles R Marmar; Thomas C Neylan; Frank B Schoenfeld
Journal:  Psychiatr Q       Date:  2002

Review 6.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 7.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 8.  Impact of Traumatic Stress on Sleep and Management Options in Women.

Authors:  Ihori Kobayashi; Mary Katherine Howell
Journal:  Sleep Med Clin       Date:  2018-06-28

9.  Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention.

Authors:  Shawn P Cahill; Kristin Pontoski; Carla M D'Olio
Journal:  Psychiatry (Edgmont)       Date:  2005-09

10.  Developmental cascades linking stress inoculation, arousal regulation, and resilience.

Authors:  David M Lyons; Karen J Parker; Maor Katz; Alan F Schatzberg
Journal:  Front Behav Neurosci       Date:  2009-09-18       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.